Sanofi gets positive results for dengue vaccine

PARIS, Nov 6 (Reuters) - Sanofi Pasteur, the vaccines division of France's Sanofi-Aventis Group (SASY.PA: Quote, Profile, Research, Stock Buzz), said on Tuesday it had obtained positive results for its development of a vaccine to treat dengue fever.

The results are being presented at a meeting in Philadelphia and Sanofi said it would expand its ongoing clinical trials in Asia and Latin America for the dengue treatment.

Submission to health authorities is expected in 2012.

The company said immunisation with Sanofi Pasteur's tetravalent dengue candidate vaccine generated a seroneutralising antibody response against all four serotypes of the virus responsible for dengue fever in 100 percent of adults who participated in a trial in the United States.

Dengue fever is a mosquito-borne disease affecting up to 100 million people each year and resulting in 24,000 deaths, mostly among children, according to estimates from the World Health Organization.

(Reporting by Sudip Kar-Gupta)